4//SEC Filing
Venkatesan Jay 4
Accession 0001140361-24-032293
CIK 0001601485other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 9:53 PM ET
Size
21.1 KB
Accession
0001140361-24-032293
Insider Transaction Report
Form 4
Venkatesan Jay
Director
Transactions
- Purchase
Common Warrants
2024-06-28+50,000→ 50,000 total(indirect: See footnote)Exercise: $5.00→ Common Stock (50,000 underlying) - Purchase
Pre-Funded Warrants
2024-06-28$4.99/sh+50,000$249,500→ 50,000 total(indirect: See footnote)Exercise: $0.01→ Common Stock (50,000 underlying) - Purchase
Pre-Funded Warrants
2024-06-28$4.99/sh+50,000$249,500→ 50,000 total(indirect: See footnote)Exercise: $0.01→ Common Stock (50,000 underlying) - Purchase
Pre-Funded Warrants
2024-06-28$4.99/sh+50,000$249,500→ 50,000 totalExercise: $0.01→ Common Stock (50,000 underlying) - Purchase
Pre-Funded Warrants
2024-06-28$4.99/sh+50,000$249,500→ 50,000 total(indirect: See footnote)Exercise: $0.01→ Common Stock (50,000 underlying) - Purchase
Common Warrants
2024-06-28+50,000→ 50,000 totalExercise: $5.00→ Common Stock (50,000 underlying) - Purchase
Common Warrants
2024-06-28+50,000→ 50,000 total(indirect: See footnote)Exercise: $5.00→ Common Stock (50,000 underlying) - Purchase
Common Warrants
2024-06-28+50,000→ 50,000 total(indirect: See footnote)Exercise: $5.00→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
- [F2]The Common Warrants expire on July 1, 2029.
- [F3]Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
- [F4]The Pre-Funded Warrants do not have an expiration date.
- [F5]The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
Elicio Therapeutics, Inc.
CIK 0001601485
Entity typeother
Related Parties
1- filerCIK 0001413350
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 9:53 PM ET
- Size
- 21.1 KB